Weeks after its $350-million marketing deal with Pfizer to sell its insulin products globally was called off, Biocon said it was still interested in partnering with the MNC in other areas.

Pfizer, on Monday, said it has registered a net profit of Rs.48.10 crore in the fourth quarter ended March 31, 2012, against Rs.63.14 crore in the year-ago period.

By Brett Chase May 21, 2012 1:15 pm J&J wants to sell its blood-thinning drug to help prevent heart attack and stroke in patients with a medical history.

Last week I moderated a panel called "The New Rules of Partnerships and Collaborations" at the Convergence East conference on Cape Cod, and the experience gave me a chance to probe some of the biopharma industry's top dealmakers about their preferences ...

Belgrade, Serbia - When apixaban (Eliquis, Pfizer/Bristol-Myers Squibb) won out over warfarin for preventing stroke or systemic embolism (SSE) in patients with atrial fibrillation (AF) in the ARISTOTLE trial, its benefits weren't influenced by LV ...